NDLI: Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

Please wait, while we are loading the content...

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Ehrnhoefer, Dagmar E. Wong, Bibiana K. Y. Hayden, Michael R.
Description	Country affiliation: Canada Author Affiliation: Ehrnhoefer DE ( Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child & Family Research Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada.)
Abstract	Neurodegenerative diseases, exemplified by Alzheimer's disease and Huntington's disease, are characterized by progressive neuropsychiatric dysfunction and loss of specific neuronal subtypes. Although there are differences in the exact sites of pathology, and the clinical profiles of these two conditions only partially overlap, considerable similarities in disease mechanisms and pathogenic pathways can be observed. These shared mechanisms raise the possibility of exploiting common therapeutic targets for drug development. As Huntington's disease has a monogenic cause, it is possible to accurately identify individuals who carry the Huntington's disease mutation but do not yet manifest symptoms. These individuals could act as a model for Alzheimer's disease to test therapeutic interventions that target shared pathogenic pathways.
File Format	HTM / HTML
ISSN	14741776
e-ISSN	14741784
DOI	10.1038/nrd3556
Journal	Nature Reviews Drug Discovery
Issue Number	11
Volume Number	10
Language	English
Publisher	Nature Publishing Group
Publisher Date	2011-10-21
Publisher Place	Great Britain (UK)
Access Restriction	Open
Subject Keyword	Discipline Pharmacology Discipline Biotechnology Alzheimer Disease Drug Therapy Etiology Drug Discovery Huntington Disease Pathology Animals Brain Drug Effects Enzymology Drug Delivery Systems Neural Pathways Protein Kinase Inhibitors Administration & Dosage Tor Serine-threonine Kinases Antagonists & Inhibitors Metabolism
Content Type	Text
Resource Type	Article
Subject	Medicine Drug Discovery Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Convergent pathogenic pathways in Alzheimer’s and Huntington disease: Shared targets for drug development

Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Neurodegenerative diseases: New kinase targets for Alzheimer's disease.

Targeting the phosphoinositide 3-kinase pathway in cancer.

PI3K and cancer: lessons, challenges and opportunities.

Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.

Rapamycin passes the torch: a new generation of mTOR inhibitors.

Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster.

Targeting PI3 kinase in cancer.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

Similar Documents

Convergent pathogenic pathways in Alzheimer’s and Huntington disease: Shared targets for drug development

Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Neurodegenerative diseases: New kinase targets for Alzheimer's disease.

Targeting the phosphoinositide 3-kinase pathway in cancer.

PI3K and cancer: lessons, challenges and opportunities.

Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.

Rapamycin passes the torch: a new generation of mTOR inhibitors.

Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster.

Targeting PI3 kinase in cancer.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.